81093-37-0

• 常用中文名：普伐他汀
• 常用英文名：Pravastatin
• CAS号：81093-37-0
• 分子式：C₂₃H₃₆O₇
• 分子量：424.53
• 相关类别： 原料药 循环系统用药 调节血脂药
• 发布时间：2018-04-03 08:00:00
• 更新时间：2026-07-02 13:08:39
• Pravastatin是HMG-CoA还原酶抑制剂,对甾醇合成的IC50为5.6 μM。

名称

• 中文名: 普伐他汀
• 英文名: pravastatin
• 中文别名: 帕伐他丁; 美百乐镇; (+)-(3R,5R)-3,5-二羟基-7-[(1S,2S,6S,8S,8aR)-6-羟基-2-甲基-8-[(S)-2-甲基丁酰氧基]-1,2,6,7,8,8a-六氢-1-萘]-庚酸; (+)-(3R,5R)-3,5-二羟基-7-[(1S,2S,6S,8ΑR)-6-羟基-2-甲基-8-[(S)-2-甲基丁酰氧基]-1,2,6,7,8,8Α-六氢-1-萘基]庚酸钠; 怕瓦停普拉司丁; (+)-(3R,5R)-3,5-二羟基-7-[(1S,2S,6S,8S,8-6-羟基-2-甲基-8-[(S)-2-甲基丁酰氧基]-1,2,6,7,8,8a-六氢-1-萘]-庚酸; 萘维太定
• 英文别名: PRAVACHOL; (3R,5R)-3,5-Dihydroxy-7-[(1S,2S,6S,8S,8aR)-6-hydroxy-2-methyl-8-{[(2S)-2-methylbutanoyl]oxy}-1,2,6,7,8,8a-hexahydro-1-naphthalenyl]heptanoic acid; PRAVASTATIN(RG); Oliprevin; 3b-Hydroxycompactin; 1-Naphthalenehtanoic acid, 1,2,6,7,8,8a-hexahydro-b,d,6-trihydroxy-2-methyl-8-[(2S)-2-methyl-1-oxobutoxy]-, (bR,dR,1S,2S,6S,8S,8)- (9CI); (3R,5R)-7-[(1S,2S,6S,8S,8aR)-6-hydroxy-2-methyl-8-[(2S)-2-methylbutanoyl]oxy-1,2,6,7,8,8a-hexahydronaphthalen-1-yl]-3,5-dihydroxyheptanoic acid; 1-Naphthalenehtanoic acid, 1,2,6,7,8,8a-hexahydro-b,d,6-trihydroxy-2-methyl-8-(2-methyl-1-oxobutoxy)-, [1S-[1a(bS*,dS*),2a,6a,8b(R*),8aa]]; PRAVASTATIN (CS-514); (3R,5R)-3,5-dihydroxy-7-((1S,2S,6S,8S,8-6-hydroxy-2-Methyl-8-(((S)-2-Methylbutanoyl)oxy)-1,2,6,7,8,8a-hexahydronaphthalen-1-yl)htanoic acid; (3R,5R)-3,5-dihydroxy-7-[(1S,2S,6S,8S)-6-hydroxy-2-methyl-8-[(2S)-2-methyl-1-oxobutoxy]-1,2,6,7,8,8a-hexahydronaphthalen-1-yl]htanoic acid; [3H]-Pravastatin; (BET, DELT,1S,2S,6S,8S,8-1,2,6,7,8,8A-HEXAHYDRO-BETA, DELTA,6-TRIHYDROXY-2-METHYL-8[(2S)-2-METHYL-1-OXOBUTOXYL]-1-NAPHTHALENEHTANOIC ACID SODIUM; (BETA R,DELTA R,1S,2S,6S,8S,8-1,2,6,7,8,8A-HEXAHYDRO-BETA,DELTA,6-TRIHYDROXY-2-METHYL-8-[(2S)-2-METHYL-1-OXOBUTOXY]-1-NAPHTHALENEHTANOIC ACID MONOSODIUM SALT; sodium(+)-(3R，5R)-3，5-Dihydroxy-7-[(1S，2S，6S，8αR)-6-hydroxy-2-methyl-8-[(S)-2-methyl-hutyryloxy]1，2，6，7，8，8α-hexahydro-1-naphthyl]htanoate; Pravatatin; Pravastatine; Pravastatinum [Latin]; 1-Naphthalenehtanoic acid, 1,2,6,7,8,8a-hexahydro-β,δ,6-trihydroxy-2-methyl-8-[(2S)-2-methyl-1-oxobutoxy]-, (βR,δR,1S,2S,6S,8S,8); PRAVASTATIN FREE BASE; PravastatinQ: What is Pravastatin Q: What is the CAS Number of Pravastatin; [14C]-Pravastatin; MFCD00887601; 3β-Hydroxycompactin Sodium salt; Pravastatina; [1s-[1a(bs,ds),2a,6b,8b(r),8aa]]-1,2,6,7,8,8a-hexahydro-b,d,6-trihydroxy-2-methyl-8-(2-methyl-1-oxobutoxy)-1-naphthalenehtanoic acid monosodium salt; (BETA-R,DELTA-R,1S,2S,6S,8S,8-1,2,6,7,8,8A-HEXAHYDRO-BETA,DELTA,6-TRIHYDROXY-2-METHYL-8[(2S)-2-METHYL-1-OXOBUTOXYL]-1-NAPHTHALENEHTANOIC ACID NA; 3BETA-HYDROXYCOMPACTIN, NA; Pravachol; Pravastatinum; (3R,5R)-3,5-Dihydroxy-7-[(1S,2S,6S,8S,8aR)-6-hydroxy-2-methyl-8-{[(2S)-2-methylbutanoyl]oxy}-1,2,6,7,8,8a-hexahydronaphthalen-1-yl]heptanoic acid; PRAVASELECT; MEVALOTIN; Pravastatine [French]; TASTATIN SODIUM; Pravastatina [Spanish]; Pravastatin //BP; (3R,5R)-3,5-dihydroxy-7-{(1S,2S,6S,8S,8aR)-6-hydroxy-2-methyl-8-[(2S)-2-methylbutanoyloxy]-1,2,6,7,8,8a-hexahydronaphthalen-1-yl}heptanoic acid; PRAVASTATIN; (3R,5R)-7-[(1S,2R,6S,8S,8-6-hydroxy-2-methyl-8-[(2S)-2-methylbutanoyl]oxy-1,2,6,7,8,8a-hexahydronaphthalen-1-yl]-3,5-dihydroxy-htanoic acid; ELISOR; Pravastatin-D9; (1S,βR,δR,8aβ)-1,2,6,7,8,8a-Hexahydro-β,δ,6β-trihydroxy-2β-methyl-8α-[(S)-2-methyl-1-oxobutoxy]-1β-naphthalenehtanoic acid; (+)-(3r,5r)-3,5-dihydroxy-7-[(1s,2s,6s,8s,8-6-hydroxy-2-methyl-8-[(s)-2-methylbutyryloxy]-1,2,6,7,8,8a-hexahydro-1-naphthyl]-htanoic acid; KOPOSTAT; Eptastatin

物化性质

• 密度: 1.2±0.1 g/cm3
• 沸点: 634.5±55.0 °C at 760 mmHg
• 熔点: 171.2-173ºC
• 分子式: C₂₃H₃₆O₇
• 分子量: 424.53
• 闪点: 213.2±25.0 °C
• PSA: 127.12000
• LogP: 1.35
• 外观性状: 白色粉末
• 蒸汽压: 0.0±4.2 mmHg at 25°C
• 折射率: 1.555
• 储存条件: 2-8°C
• 水溶解性: H2O: 19 mg/mL

生物活性

• 描述: Pravastatin是HMG-CoA还原酶抑制剂,对甾醇合成的IC50为5.6 μM。
• 相关类别:
  信号通路 >> 代谢酶/蛋白酶 >> HMG-CoA还原酶(HMGCR)
  研究领域 >> 心血管疾病
• 参考文献:

  [1]. McTavish D, et al. Pravastatin. A review of its pharmacological properties and therapeutic potential in hypercholesterolaemia. Drugs. 1991 Jul;42(1):65-89.

安全

• 危害码 (欧洲): F: Flammable;C: Corrosive;
• 风险声明 (欧洲): R11;R34
• 安全声明 (欧洲): S16-S26-S36/37/39-S45
• WGK德国: 2
• RTECS号: QJ7185000

合成路线

81131-70-6 ~% 81093-37-0

文献：WO2005/121062 A2, ; Page/Page column 6 ;

73573-88-3 ~88% 81093-37-0

文献：Biocon Limited; Tiwari, Sanjay; Patale, Mukesh Babuappa; Garg, Saurabh; Garg, Mayank Kumar; Joshi, Sulekha; Kumar, Chittnalli Ramegowda Naveen; Kumar, Bimal; Goel, Anuj; Iyer, Harish Patent: US2014/141467 A1, 2014 ; Location in patent: Page/Page column ;

84173-31-9 ~% 81093-37-0

文献：Journal of Antibiotics, , vol. 50, # 12 p. 1032 - 1035

上下游产品

上游产品  2
81131-70-6 73573-88-3
下游产品  2
85956-22-5 81131-70-6

制备

【方法一】
从ML-236B(compactin)微生物氢氧化得到。
将M.hiemalis SANK36372植入20个500ml的锥形瓶中，每个锥形瓶装有100ml的TS溶液。该溶液组成为1.0%葡萄糖、0.2%Polypepton (Daigo Nutritive Chemicals产品)、0.1%肉萃和0.3%玉米浸液。在旋转器中(220rpm)，于26℃培养3d后，在每只瓶中加入500μg/ml的ML-236B，再培养5d。转化的情况可用硅胶TLC检测，展开剂为苯-丙酮-丙酸(50：50：3)，ML-236B及其转化产物(即Pravastatin)的Rf分别值为0.6和0.45。发酵液合并后过滤，滤液(1.9 L)用2mol/L盐酸调至pH=3.0后，用3份各1L的乙酸乙酯提取。提取液用饱和氯化钠水溶液洗后，加入催化量的三氟乙酸，使转化产物内酯化。形成的溶液再用5%碳酸氢钠水溶液洗，无水硫酸钠干燥，减压浓缩至干。剩余物制备液相色谱层析，70%苯的丙酮溶液洗脱。收集含产物的洗脱液，结晶得455mg无色结晶，收率43.7%。紫外及核磁共振等显示该结晶为普伐他汀。